GENinCode (LON:GENI) Shares Down 8.6% – Here’s What Happened

GENinCode Plc (LON:GENI)’s stock price dropped 8.6% during mid-day trading on Friday . The company traded as low as GBX 0.80 and last traded at GBX 0.80. 3,159,584 shares changed hands during trading, a decline of 45% from the average daily volume of 5,785,926 shares. The stock had previously closed at GBX 0.88.

GENinCode Stock Down 8.6%

The firm has a market capitalization of £6.02 million, a PE ratio of -0.38 and a beta of 0.59. The company has a debt-to-equity ratio of 117.74, a quick ratio of 15.88 and a current ratio of 0.93. The business’s 50 day moving average price is GBX 0.95 and its 200-day moving average price is GBX 1.15.

GENinCode (LON:GENI) last issued its quarterly earnings results on Monday, June 8th. The company reported GBX (2.08) EPS for the quarter. GENinCode had a negative net margin of 185.47% and a negative return on equity of 409.40%. The business had revenue of GBX 308 million during the quarter. As a group, equities research analysts forecast that GENinCode Plc will post -7.1299999 earnings per share for the current year.

GENinCode Company Profile

GENinCode Plc is a UK based company specialising in genetic risk assessment of cardiovascular disease. Cardiovascular disease is the leading cause of death and disability worldwide.

GENinCode operates business units in the UK, in the United States through GENinCode U.S. Inc and in Europe through GENinCode S.L.U.

GENinCode predictive technology provides patients and physicians with globally leading preventative care and treatment strategies. GENinCode CE marked invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict disease onset.